Descartes 33
Alternative Names: Descartes-33Latest Information Update: 05 Mar 2021
At a glance
- Originator Cartesian Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Respiration disorders
Most Recent Events
- 26 Feb 2021 Descartes 33 is available for licensing as of 26 Feb 2021. https://www.cartesiantherapeutics.com/investors-developing-cancer-solutions/#partners
- 26 Feb 2021 Preclinical trials in Respiration disorders in USA (Parenteral), prior to February 2021 (Cartesian Therapeutics pipeline, February 2021)
- 26 Feb 2021 Preclinical trials in Autoimmune disorders in USA (Parenteral), prior to February 2021 (Cartesian Therapeutics pipeline, February 2021)